文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

腹膜内注射124I-omburtamab在促结缔组织增生性小圆细胞肿瘤患者中的生物分布与辐射剂量学

Biodistribution and Radiation Dosimetry of Intraperitoneally Administered 124I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.
PubMed 文献 · J Nucl Med · 2021-12-02

本研究在31例腹膜受累的促结缔组织增生性小圆细胞肿瘤患者中,于131I-omburtamab腹膜内放射免疫治疗前给予约74 MBq 124I-omburtamab腹膜内注射,行系列PET/CT及血样采集,用OLINDA/EXM计算器官吸收剂量。结果显示腹膜腔自身剂量为0.58 ± 0.19 mGy/MBq,全身有效剂量为0.31 ± 0.10 mSv/MBq,主要器官系统分布和活性较低。结论认为124I-omburtamab腹膜内PET/CT可在治疗前评估腹膜内分布并估算腹膜腔及正常器官的吸收剂量。

要点

  • 31例腹膜受累的促结缔组织增生性小圆细胞肿瘤患者纳入本研究。
  • 腹膜腔自身剂量为0.58 ± 0.19 mGy/MBq,全身有效剂量为0.31 ± 0.10 mSv/MBq。
  • 124I-omburtamab腹膜内PET/CT可在治疗前评估腹膜内分布并估算吸收剂量。

核心结论

  • 腹膜内给予124I-omburtamab行PET/CT成像,可在治疗前评估腹膜内分布并估算腹膜腔及正常器官的吸收剂量。

研究设计与样本

  • 本研究为一项131I-omburtamab腹膜内放射免疫治疗的I期试验,纳入腹膜受累的促结缔组织增生性小圆细胞肿瘤患者。
  • 患者在甲状腺阻断后、放射免疫治疗前接受约74 MBq的124I-omburtamab腹膜内注射,注射后至144小时行5次系列PET/CT扫描,至120小时采集多份血样,用OLINDA/EXM计算器官吸收剂量。
  • 共研究31例患者。

主要发现

  • 血液药代动力学呈双相模式:初始上升相中位半衰期为23 ± 15小时,随后下降相中位半衰期为56 ± 34小时。
  • 大多数患者腹膜内分布不均匀且呈弥漫性。
  • 腹膜腔自身剂量为0.58 ± 0.19 mGy/MBq。
  • 全身分布和主要器官活性较低,肝脏中位吸收剂量为0.72 ± 0.23 mGy/MBq,脾脏为0.48 ± 0.17 mGy/MBq,肾脏为0.57 ± 0.12 mGy/MBq。
  • 平均有效剂量为0.31 ± 0.10 mSv/MBq,全身和腹膜腔生物学半衰期分别为45 ± 9小时和24 ± 5小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to assess the pharmacokinetics, biodistribution, and radiation dosimetry of 124I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumor. Methods: Eligible patients diagnosed with desmoplastic small round cell tumor with peritoneal involvement were enrolled in a phase I trial of intraperitoneal radioimmunotherapy with 131I-omburtamab. After thyroid blockade and before radioimmunotherapy, patients received approximately 74 MBq of 124I-omburtamab intraperitoneally. Five serial PET/CT scans were obtained up to 144 h after injection. Multiple blood samples were obtained up to 120 h after injection. Organ-absorbed doses were calculated with OLINDA/EXM. Results: Thirty-one patients were studied. Blood pharmacokinetics exhibited a biphasic pattern consisting of an initial rising phase with a median half-time (±SD) of 23 ± 15 h and a subsequent falling phase with a median half-time of 56 ± 34 h. Peritoneal distribution was heterogeneous and diffuse in most patients. Self-dose to the peritoneal cavity was 0.58 ± 0.19 mGy/MBq. Systemic distribution and activity in major organs were low. The median absorbed doses were 0.72 ± 0.23 mGy/MBq for liver, 0.48 ± 0.17 mGy/MBq for spleen, and 0.57 ± 0.12 mGy/MBq for kidneys. The mean effective dose was 0.31 ± 0.10 mSv/MBq. Whole-body and peritoneal cavity biologic half-times were 45 ± 9 and 24 ± 5 h, respectively. Conclusion: PET/CT imaging with intraperitoneally administered 124I-omburtamab enables assessment of intraperitoneal distribution and estimation of absorbed dose to peritoneal space and normal organs before therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Grkovski M, Modak S, Zanzonico PB, et al. Biodistribution and Radiation Dosimetry of Intraperitoneally Administered 124I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors. J Nucl Med. 2021. PMID: 34857661. doi:10.2967/jnumed.121.262793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。